权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Inhibin function in tumor angiogenesis

抑制素在肿瘤血管生成中的作用

基本信息

批准号：
10543048
负责人：
Mythreye Karthikeyan
金额：
$ 33.55万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-07-01 至 2024-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10543048
关键词：
Angiogenesis Inhibitors Antibodies Ascites Binding Biochemical Biological Assay Biological Markers Blood Vessels Bypass Cancer Model Cancer cell line Clinic Clinical Complex Data ENG gene Endocrine Endoglin Endothelial Cells Endothelium Exhibits Family Family member Gene Expression Profiling Genes Goals Growth Factor HIF1A gene Hormones Human Hypoxia In Vitro Investigation Knowledge Ligands Malignant Female Reproductive System Neoplasm Malignant Neoplasms Malignant neoplasm of ovary Mediating Mediator Menopause Molecular Neoplasm Metastasis Ovarian Pathway interactions Patients Pharmaceutical Preparations Postmenopause Process Prognostic Marker Receptor Cell Resistance Role Signal Transduction Testing Therapeutic Toxic effect Transcriptional Regulation Transforming Growth Factor beta Transforming Growth Factor beta Receptors Tumor Angiogenesis Tumor Suppression Vascular Endothelial Growth Factors Woman Xenograft procedure angiogenesis autocrine bevacizumab biophysical techniques cancer cell diagnostic biomarker gain of function improved in vitro Assay in vivo inhibin insight loss of function neoplastic cell neutralizing antibody novel novel therapeutics ovarian neoplasm overexpression paracrine promoter receptor response side effect small hairpin RNA targeted treatment therapeutic target transcription factor transcriptomics tumor tumor growth tumor progression

项目摘要

Ovarian cancer is among the most devastating of gynecological cancers primarily impacting postmenopausal women. Induction of angiogenesis, the process of generating and remodeling blood vessels, is a critical requirement for tumor growth and metastasis in multiple cancers including ovarian, leading to the use anti- angiogenic agents in the clinic. However side effects and toxicities can limit their use. Thus there remains a need to identify cancer specific, safe ways to control angiogenesis in ovarian cancer. Inhibin is a unique TGF-β family member whose levels are extremely low in normal post-menopausal women. However Inhibin is an established biomarker for ovarian cancers with unknown functions. Our preliminary studies show that Inhibin expression is regulated by hypoxia, a well-appreciated regulator of tumor angiogenesis. We find that Inhibin exhibits paracrine effects on the endothelium by increasing angiogenesis in vitro and in vivo. Mechanistically, Inhibin requires the endothelial specific receptors Endoglin and Alk1 to induce angiogenesis. Since Inhibin is expressed in ovarian cancers, but present at low systemic levels in normal post-menopausal women we will examine Inhibin as a potential novel angiogenic target for cancer the mechanism of action. The hypothesis to be tested is that blocking tumoral Inhibin, a novel ligand for endothelial specific TGF-β receptors, and a product of the hypoxia adaptive response that promotes angiogenesis will result in suppression of tumor angiogenesis. The specific aims are: 1) To test if blocking Inhibin has therapeutic anti-angiogenic effects in ovarian cancer alone or in combination with current anti-angiogenic therapies. 2) To delineate the mechanism of Inhibin induced endothelial cell remodeling and angiogenesis using a combination of cell signaling, biochemical and biophysical approaches to test Inhibin as a direct novel ligand for endothelial receptors endoglin and Alk1 and identify novel signaling targets of Inhibin using transcriptomics. 3) To define hypoxia mechanisms regulating Inhibin expression. I believe that these investigations into Inhibin-mediated angiogenesis will provide the first insights into previously unknown functions for Inhibin that is broadly expressed in cancer and provide new targets to safely treat angiogenesis in cancer.

卵巢癌是最具破坏性的妇科癌症之一，主要影响绝经后

项目成果

期刊论文数量（10）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

A bioinformatic analysis of the inhibin-betaglycan-endoglin/CD105 network reveals prognostic value in multiple solid tumors.

DOI：
10.1371/journal.pone.0249558
发表时间：
2021
期刊：
PloS one
影响因子：
3.7
作者：
Listik E;Horst B;Choi AS;Lee NY;Győrffy B;Mythreye K
通讯作者：
Mythreye K

Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer.

DOI：
10.1038/s41388-018-0316-y
发表时间：
2018-08
期刊：
Oncogene
影响因子：
8
作者：
Serrao A;Jenkins LM;Chumanevich AA;Horst B;Liang J;Gatza ML;Lee NY;Roninson IB;Broude EV;Mythreye K
通讯作者：
Mythreye K

Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers.

DOI：
10.1038/s42003-022-03495-6
发表时间：
2022-06-02
期刊：
Communications biology
影响因子：
5.9
作者：
通讯作者：

Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment.

DOI：
10.1016/j.semcancer.2022.03.004
发表时间：
2022-11
期刊：
SEMINARS IN CANCER BIOLOGY
影响因子：
14.5
作者：
Monavarian, Mehri;Elhaw, Amal Taher;Tang, Priscilla W.;Javed, Zaineb;Shonibare, Zainab;Scalise, Carly Bess;Arend, Rebecca;Jolly, Mohit Kumar;Sewell-Loftin, Mary Kathryn;Hempel, Nadine;Mythreye, Karthikeyan
通讯作者：
Mythreye, Karthikeyan

Dually modified transmembrane proteoglycans in development and disease.